File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Prior gastroscopy and mortality in patients with gastric cancer: a matched retrospective cohort study

TitlePrior gastroscopy and mortality in patients with gastric cancer: a matched retrospective cohort study
Authors
Issue Date2018
PublisherMosby, Inc. The Journal's web site is located at http://www.elsevier.com/locate/gie
Citation
Gastrointestinal Endoscopy, 2018, v. 87 n. 1, p. 119-127, e3 How to Cite?
AbstractBackground and Aims The role of prior gastroscopy on the outcome of patients with gastric cancer remains unknown. This study determines the association between intervals of prior gastroscopy and mortality in patients with gastric cancer. Methods We identified 20,066 newly diagnosed patients with gastric cancer in the National Health Insurance Database of Taiwan between 2002 and 2007. After we excluded patients who had gastroscopies performed ≤6 months before the diagnosis of cancer, patients were matched into 3 cohorts according to the intervals of prior gastroscopy: 6 months to 2 years (<2 Y cohort), 2 to 5 years (2-5 Y cohort), and none within the previous 5 years (>5 Y cohort). The 3 cohorts were matched for age, curative treatment for gastric cancer, Helicobacter pylori therapy, and propensity scores comprised of sex, comorbidities, and concomitant medication usage. The primary outcome is the hazard ratio (HR) of all-cause mortality. Results After matching, we identified 1286, 1286, and 5144 patients for the <2 Y, 2 to 5 Y, and >5 Y cohorts. Compared with the >5 Y cohort, the HR of all-cause mortality for the <2 Y and 2 to 5 Y cohorts was 0.80 (95% confidence interval [CI], 0.72-0.89; P <.001) and 0.83 (95% CI, 0.76-0.91; P <.001), respectively. The HRs of gastric cancer-specific mortality were significantly lower in the <2 Y (0.80; 95% CI, 0.71-0.91; P <.001) and 2 to 5 Y cohorts (0.83; 95% CI, 0.75-0.93; P <.001). Conclusions Patients with gastric cancer who had a gastroscopy performed within 5 years before the cancer diagnosis had significantly lower mortality. Our results may support the role of repeat endoscopic examination or surveillance endoscopy in selected patients. © 2018 American Society for Gastrointestinal Endoscopy
Persistent Identifierhttp://hdl.handle.net/10722/243153
ISSN
2017 Impact Factor: 7.204
2015 SCImago Journal Rankings: 2.390
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorLeung, WK-
dc.contributor.authorHo, HJ-
dc.contributor.authorLin, JT-
dc.contributor.authorWu, MS-
dc.contributor.authorWu, CY-
dc.date.accessioned2017-08-25T02:50:46Z-
dc.date.available2017-08-25T02:50:46Z-
dc.date.issued2018-
dc.identifier.citationGastrointestinal Endoscopy, 2018, v. 87 n. 1, p. 119-127, e3-
dc.identifier.issn0016-5107-
dc.identifier.urihttp://hdl.handle.net/10722/243153-
dc.description.abstractBackground and Aims The role of prior gastroscopy on the outcome of patients with gastric cancer remains unknown. This study determines the association between intervals of prior gastroscopy and mortality in patients with gastric cancer. Methods We identified 20,066 newly diagnosed patients with gastric cancer in the National Health Insurance Database of Taiwan between 2002 and 2007. After we excluded patients who had gastroscopies performed ≤6 months before the diagnosis of cancer, patients were matched into 3 cohorts according to the intervals of prior gastroscopy: 6 months to 2 years (<2 Y cohort), 2 to 5 years (2-5 Y cohort), and none within the previous 5 years (>5 Y cohort). The 3 cohorts were matched for age, curative treatment for gastric cancer, Helicobacter pylori therapy, and propensity scores comprised of sex, comorbidities, and concomitant medication usage. The primary outcome is the hazard ratio (HR) of all-cause mortality. Results After matching, we identified 1286, 1286, and 5144 patients for the <2 Y, 2 to 5 Y, and >5 Y cohorts. Compared with the >5 Y cohort, the HR of all-cause mortality for the <2 Y and 2 to 5 Y cohorts was 0.80 (95% confidence interval [CI], 0.72-0.89; P <.001) and 0.83 (95% CI, 0.76-0.91; P <.001), respectively. The HRs of gastric cancer-specific mortality were significantly lower in the <2 Y (0.80; 95% CI, 0.71-0.91; P <.001) and 2 to 5 Y cohorts (0.83; 95% CI, 0.75-0.93; P <.001). Conclusions Patients with gastric cancer who had a gastroscopy performed within 5 years before the cancer diagnosis had significantly lower mortality. Our results may support the role of repeat endoscopic examination or surveillance endoscopy in selected patients. © 2018 American Society for Gastrointestinal Endoscopy-
dc.languageeng-
dc.publisherMosby, Inc. The Journal's web site is located at http://www.elsevier.com/locate/gie-
dc.relation.ispartofGastrointestinal Endoscopy-
dc.titlePrior gastroscopy and mortality in patients with gastric cancer: a matched retrospective cohort study-
dc.typeArticle-
dc.identifier.emailLeung, WK: hku75407@hku.hk-
dc.identifier.authorityLeung, WK=rp01479-
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1016/j.gie.2017.06.013-
dc.identifier.pmid28648576-
dc.identifier.scopuseid_2-s2.0-85027111114-
dc.identifier.hkuros273705-
dc.identifier.volume87-
dc.identifier.issue1-
dc.identifier.spage119-
dc.identifier.epage127, e3-
dc.identifier.isiWOS:000417961100016-
dc.publisher.placeUnited States-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats